[Precurarization of @entity2900 with XXXX : the influence of the precurarization interval].

@entity1 @entity24662 @entity1109 @entity5740 @entity282 @entity2901 @entity925 @entity2897 @entity912 @entity2900
PURPOSE: To determine the influence of two different pretreatment intervals, i.e. 3 and 6 min, on the efficacy of 0.01 mg/kg @entity2897 in preventing @entity2900 -induced @entity2901 and @entity925 . METHODS: A total of 60 adult @entity1 were randomized and received either 0.01 mg/kg @entity2897 (0.2*ED(95)) i.v. ( @entity5740 group: pretreatment interval 3 min, @entity24662 group: pretreatment interval 6 min) or normal saline i.v. (placebo group) prior to injection of @entity2900 . The incidence and severity of @entity2901 and @entity925 and side-effects of precurarization were assessed. RESULTS: The incidence of @entity2901 was only reduced in the @entity24662 group (45%) compared with the Placebo group (85%), p<0.05. @entity2897 was associated with a higher incidence of @entity1109 in both pretreatment groups ( @entity5740 : 75%, @entity24662 : 80%) compared with the Placebo group (30%), p<0.05. CONCLUSION: @entity2897 is only effective in preventing @entity2900 -induced @entity2901 when a longer pretreatment interval, i.e. 6 min instead of 3 min, is chosen. Precurarization led to signs of @entity912 in both pretreatment groups in the majority (75-80%) of @entity1 without reducing the incidence or severity of @entity282 .
